title: Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.
authors.affiliation: Hofstra Northwell School of Medicine, Hempstead, NY kjhaveri@northwell.edu.
authors.forename: Richard
authors.initials: R
authors.lastname: Barnett
authors.affiliation: Hofstra Northwell School of Medicine, Hempstead, NY kjhaveri@northwell.edu.
authors.forename: Valerie S
authors.initials: VS
authors.lastname: Barta
authors.affiliation: Hofstra Northwell School of Medicine, Hempstead, NY kjhaveri@northwell.edu.
authors.forename: Kenar D
authors.initials: KD
authors.lastname: Jhaveri
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004379:Duodenal Neoplasms / Q000188:drug therapy*; D006801:Humans; D016030:Kidney Transplantation; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab